Similarly, in a Cancer and Leukemia Group B study, which included 196 adult AML patients from two clinical studies, WT1 mutation predicted a worse 3-year disease-free and OS compared to wild-type WT1 AML patients independently of CEBPA, FLT3-ITD, and NPM1 mutational status [32]. This evidence concerns the gene WT1 and acute myeloid leukemia.